超敏C-反应蛋白与高血压关系的病例对照研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (10): 1164-1168.

超敏C-反应蛋白与高血压关系的病例对照研究

张龙¹, 盛蕾², 陈金凤³, 杨松⁴, 沈冲³

¹南京大学医学院附属南京市鼓楼医院急诊科,南京 210008,江苏;
²江苏省第二中医院神经内科,南京 210017,江苏;
³南京医科大学公共卫生学院流行病与卫生统计学系,南京 210029,江苏;
⁴宜兴市人民医院心内科,宜兴 214200, 江苏

收稿日期:2011-07-27 修回日期:2011-08-22 出版日期:2011-10-26 发布日期:2011-11-02
通讯作者: 沈冲,男,副教授,研究方向:心血管流行病学。E-mail: sc@njmu.edu.cn
作者简介:张龙,男,主治医师,研究方向:心血管病临床急诊治疗。
基金资助:
江苏省卫生厅课题(项目号H200839);南京医科大学校基金课题重点项目(06NMU2010)

Case-control study on the relationship between high-sensitivity C-reactive protein and hypertension

ZHANG Long¹, SHENG Lei², CHEN Jin-feng³, YANG Song⁴, SHEN Chong³

¹Department of Emergency, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210009, Jiangsu, China;
²Department of Neurology, No.2 Traditional Chinese Medicine of Jiangsu, Nanjing 210017, Jiangsu, China;
³Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, Jiangsu, China;
⁴Department of Cardiology, Yixing People's Hospital, Yixing 214200, Jiangsu, China

Received:2011-07-27 Revised:2011-08-22 Online:2011-10-26 Published:2011-11-02

摘要/Abstract

摘要： 目的: 探讨超敏C-反应蛋白(hs-CRP)与高血压及血压水平的关系。方法: 病例和对照均选自社区基础上整群调查人群;采用Logistic回归模型和分层分析方法对可能影响hs-CRP水平与高血压及血压水平关系的因素进行分析。结果: hs-CRP在高血压患者及排除药物治疗的患者和对照人群中差异均无统计学意义;但女性病例组hs-CRP水平(2.67±2.82) mg/L显著高于对照组hs-CRP水平(2.14±2.35) mg/L(t=2.1034, P=0.043)。吸烟者中校正协变量后, hs-CRP水平变化与高血压的关联有显著意义, OR(95%CI)＝1.145 (1.001~1.309), P＝0.048; 排除药物治疗的患者后关联仍有显著意义, OR(95%CI)＝1.251 (1.041~1.503),P＝0.017;而较高hs-CRP水平(>2.4 mg/L) 患者高血压的患病风险也显著升高,OR 95%CI)＝5.065 (1.597~16.067),P＝0.006。在非药物治疗患者及血压正常者中,女性SBP、DBP和平均动脉压(MAP)在hs-CRP升高组和正常组中差异均有统计学意义,而在男性中未见此差异。结论: hs-CRP水平升高是高血压的重要独立危险因素,而吸烟者患病风险更高。

关键词: 高血压, 超敏C-反应蛋白, 病例对照研究

Abstract: AIM: To investigate the correlation between high-sensitivity C-reactive protein (hs-CRP) and hypertension and blood pressure variation. METHODS: A stratified cluster sampling method was conducted to select people over the age of 40 from community based population. Logistic regression and stratification analysis method were applied to evaluate the association of hs-CRP with hypertension. RESULTS: There were no statistical differences of hs-CRP between hypertensive or without medicine treatment group and control group. Remarkably, hypertensive in female had high hs-CRP level (2.67±2.82) mg/L than that of control group (2.14±2.35) mg/L,t=2.1034, P=0.043. After adjusted for covariates, Logistic regression analysis indicated that there was significant association between hs-CRP and hypertension in smoking population, OR(95%CI)=1.145(1.001-1.309), P=0.048. The association was still significant even excluding patients with medicine treatment and OR(95%CI)=1.252 (1.041-1.503), P=0.017 and elevated hs-CRP (>2.4 mg/L) increased risk of hypertension significantly as well, OR(95%CI)＝5.065(1.597-16.067), P＝0.006. For normotensives and hypertensive without medicine treatment, individuals with elevated hs-CRP (>2.4 mg/L) had higher systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial blood pressure (MAP) than that of normal hs-CRP (≤2.4 mg/L) in female whereas not in male. CONCLUSION: The finding suggests that elevated hs-CRP was an independent risk factor for hypertension and there was a strong association smoking population.

Key words: Hypertension, High sensitivity-CRP, Case-control study

中图分类号:

R544.1

张龙, 盛蕾, 陈金凤, 杨松, 沈冲. 超敏C-反应蛋白与高血压关系的病例对照研究[J]. 中国临床药理学与治疗学, 2011, 16(10): 1164-1168.

ZHANG Long, SHENG Lei, CHEN Jin-feng, YANG Song, SHEN Chong. Case-control study on the relationship between high-sensitivity C-reactive protein and hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1164-1168.

参考文献

[1] 徐鸿翔,周谅,胡伟,等. 高敏C反应蛋白与高血压的关系[J]. 中国心血管病研究,2010,8(3): 208-210.
[2] Bautista LE, Lopez-Jaramillo P, Vera LM, et al.Is C-reactive protein an independent risk factor for essential hypertension[J] ? J Hypertension, 2001, 19(5):857-861.
[3] 张伟,李锋,王玉琴,等. 二苯乙烯苷对实验性动脉粥样硬化大鼠血脂和炎症因子的调节作用[J]. 中国临床药理学与治疗学,2007,12(5): 516-520.
[4] Sesso HD, Stampfer MJ, Rosner B, et al.Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in mean[J].Hypertension, 2002, 36(5):801-807.
[5] Glynn RJ, Chae CU, Guralnik JM, et al.Pulse pressure and mortality in older people[J].Arch Intem Med, 2000, 160(18):2765-2772.
[6] Willerson JT.Systemic and local inflammation in patients with unstable atherosclerotic plaques[J].Prog Cardiovasc Dis, 2002, 44(6):469-478.
[7] Clearfield MB.C-reactive protein:a new risk assessment tool for cardiovascular disease[J]. Am Osteopath Assoc, 2005, 105(9):409-416.
[8] 范剑峰,汤圣兴,王俊,等. 原发性高血压左室肥厚患者妊娠相关血浆蛋白-A和C-反应蛋白的变化[J]. 中国临床药理学与治疗学,2009,14(2): 203-206.
[9] Retterstol L, Eikvar L, Bohn M, et al. C-reactive protein predicts death in patients with previous premature myocardial infraction: A 10 years follow-up study[J]. Atherosclerosis, 2002, 160(2):433-440.
[10] Song IU, Kim YD, Kim JS, et al. Can high-sensitivity C-reactive protein and plasma homocysteine levels independently predict the prognosis of patients with functional disability after first-ever ischemic stroke [J] ?Eur Neurol,2010,64(5):304-310.
[11] Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Eng J Med, 2000, 342(12):836-843.
[12] 姚昆, 刘丽娟, 曹务春, 等. 蒙古族中血清尿酸水平与代谢综合征及C-反应蛋白的关系研究[J]. 中华疾病控制,2009,13(3):232-235.
[13] 于晖, 姿可佳, 刘晓宁, 等. C反应蛋白与肥胖的关系的研究[J]. 中国分子心脏病学杂志,2005,5(4):609-611.

[1]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[2]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[3]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[4]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[5]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[6]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[7]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[8]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[9]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[10]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[11]	叶鹏, 谭兴, 冷岳奇, 王杨凯, 王伟忠. 基于交感神经系统的高血压非药物治疗研究现状和进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1335-1343.
[12]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[13]	崔海鞠, 马张庆, 杨魁, 汪五三, 许慧芳, 栾家杰. 褪黑素在非杓型自发性高血压大鼠体内的时辰药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(12): 1337-1343.
[14]	印清, 杜荣增. 机械敏感性离子通道Piezo1在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1414-1421.
[15]	张俊秀, 沈媛媛, 杨解人, 郑书国, 郝伟. 联用芝麻素和维生素E抑制PI3K/AKT信号通路改善自发性高血压大鼠的左室纤维化[J]. 中国临床药理学与治疗学, 2020, 25(11): 1214-1222.